- Supported exchanges /
- F /
- 61Y.F
MARINUS PHARMAC. DL-001 (61Y F) stock market data APIs
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
MARINUS PHARMAC. DL-001 Financial Data Overview
| 0.316 | |
| 0.316 | |
| - | |
| 0.316 | |
| 0.316 | |
| 0.282-10.1 | |
| 15 534 K | |
| 55 084 K | |
| 30 263 K | |
| 1.135 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
MARINUS PHARMAC. DL-001 Fundamental Data is available in our Financial Data APIs
- Net Revenue 30 263 K
- EBITDA -128 656 000
- Earnings Per Share -2.46
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get MARINUS PHARMAC. DL-001 Earnings via APIs
- Latest Release 2024-11-05
- EPS/Forecast NaN
Get MARINUS PHARMAC. DL-001 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
